Molecular Vision 2010; 16:2402-2411 <>
Received 4 October 2010 | Accepted 11 November 2010 | Published 17 November 2010

The role of macrophage migration inhibitory factor in ocular surface disease pathogenesis after chemical burn in the murine eye

Sei Yeul Oh,1 Jong-Sun Choi,2 Eo-Jin Kim,2 Roy S. Chuck,3 Choul Yong Park4

1Department of Ophthalmology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; 2Department of Pathology, Dongguk University Seoul, Graduate School of Medicine, Seoul, South Korea; 3Department of Ophthalmology and Visual Sciences, Montefiore Medical Center and Albert Einstein College of Medicine, New York, NY; 4Department of Ophthalmology, Dongguk University Seoul, Graduate School of Medicine, Seoul, South Korea

Correspondence to: Choul Yong Park M.D., Department of Ophthalmology, Dongguk University Ilsan Hospital, Dongguk University, Graduate School, Seoul 814, Siksadong, Ilsan-dong-gu, Koyang, Kyunggido, South Korea, 410-773; Phone: 82-31-961-7395; FAX: 82-31-961-7977; email:


Purpose: To evaluate the role of macrophage migration inhibitory factor (MIF) in the wound healing process following severe chemical burns to the ocular surface.

Methods: Chemical burning of the ocular surface was induced in mice (C57BL/6) via the application of 0.1 M NaOH. Macrophage migration inhibitory factor (MIF), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) mRNA expression in the ocular surface and lacrimal gland was evaluated via real-time reverse transcription PCR on days 2, 7, and 30 after induction of the chemical burn. The expression of MIF protein in the ocular surface and lacrimal gland was evaluated via western blot analysis. Immunohistochemical staining was conducted to detect MIF and vasculoendothelial growth factor in the cornea during the wound healing process. The angiogenic role of MIF was further evaluated using an 8–0 polyglactin suture technique to induce corneal neovascularization.

Results: MIF, TNF-α, and IL-1β mRNA expression were elevated significantly in the ocular surface up to day 30 after chemical burn induction. TNF-α alone was elevated in the lacrimal gland. MIF protein elevation was confirmed via western blot analysis, and the spatial similarity of MIF and VEGF expression in the cornea was noted during the wound healing process. 8–0 polyglactin sutures soaked in MIF induced significantly higher numbers of new vessels on the mouse cornea after 7 days (p=0.003, Mann–Whitney test).

Conclusions: These findings indicate that MIF performs a crucial role in wound healing on the ocular surface after the induction of chemical burns.


Macrophage migration inhibitory factor (MIF) was initially described as a soluble factor identified during the delayed hypersensitivity reaction [1]. The presence of macrophages at the inflamed site is the origin of the nomenclature of this interesting cytokine [1,2]. Therefore, the role of MIF was initially recognized as a unique pro-inflammatory cytokine and was considered essential for T-cell activation. However, the results of recent studies have revealed that the role of MIF is not limited to inflammation; rather, it is also profoundly involved in the regulation of cellular growth [2], wound healing [3], tissue development, and even tumor formation under a variety of pathologic conditions [4]. Previous investigations have revealed MIF expression in a variety of tissues, including the brain, ear, lung, breast, liver, testis, vascular endothelial cell, vascular smooth muscle cells, skin, kidney, endocrine glands (pituitary gland, adrenal cortex, and pancreas), and eye (lens, cornea, iris, ciliary body, lacrimal gland, and retina) [5,6].

The vital function of MIF in the wound healing process was studied previously. Elevated local levels of MIF were associated with elevated inflammatory response and marked delays in wound healing in human and mouse skin wound models [3]. On the other hand, other studies have demonstrated that MIF promotes fibroblast migration and accelerates skin wound healing [7,8]. A close relationship between MIF and vascular endothelial growth factor (VEGF) expression has recently been reported [9,10].

The wound healing response after tissue injury is critical to the individuals’ survival. In nonocular tissues, the cicatrical change accompanying new vessels and strong fibrosis may be beneficial, providing superior structural stability. However, considering the transparent nature of the cornea and the smooth and wet conjunctival surface of the normal ocular environment, it is clearly necessary to minimize fibrosis and new vessels in the process of wound healing following ocular surface trauma. One good example of this is chemical burns to the ocular surface, especially those induced by alkaline agents. This condition characterized by severe inflammation disrupts or destroys the normal homeostasis of corneal and conjunctival epithelial cells [11]. The induced deficiency of the limbal stem cell population of corneal epithelium results in clinically significant opacity, new vessel formation, and persistent epithelial corneal defects [11-13]. The cicatrical change in the conjunctiva results in tear film abnormalities and dry eye [11-13].

During the wound healing process, many cytokines secreted either from ocular resident cells or from recruited inflammatory cells are involved in the pathogenesis. Tumor necrosis factor- α (TNF- α), interleukin-1 (IL-1), interleukin-6, interleukin-10, and VEGF are some of the cytokines that were previously studied extensively in ocular chemical burn experiments [14-18]. And MIF is also a strong candidate molecule. Because MIF is also closely related to both fibrosis and neovascularization [7-10], the role of MIF in ocular wound healing was previously studied. MIF expression in the cornea was upregulated in animal models after mechanical corneal damage or infection [19,20]. MIF knockout mice exhibited reduced corneal neovascularization relative to the wild-type mice following corneal nylon suture or alkali burn [19]. These studies implied that MIF might perform an important function in ocular cicatrical changes occurring after trauma.

Recently our group reported a high level of MIF expression in the normal murine lacrimal gland and a dynamic change of MIF expression in an experimentally induced murine dry eye model [6,21,22]. In previous studies we induced local change in the lacrimal gland via a focal injection of botulinum toxin type B into the main lacrimal gland. This induced experimental dry eye and was associated with the sustained elevation of MIF expression within the lacrimal glands. However, no significant changes in MIF in the ocular surface were detected [21,22]. In a clinical setting, dry eye and chemical burn differ profoundly in pathogenesis. Chemical burns destroy the ocular surface far beyond the extent of dry eye. Although no significant role for MIF on the ocular surface was detected in our dry eye model, the role of MIF in chemical burns could differ profoundly.

In the present study we induced severe inflammation on the ocular surface via the induction of chemical burns (NaOH) in mice. We explored the expression of MIF, TNF-α, and IL-1 both in the ocular surface and lacrimal gland via real-time reverse transcription PCR (real-time RT–PCR) and western blot analysis. Vascularization of the cornea is the ultimate result of severe ocular surface inflammation, and VEGF is considered a major regulator of new corneal vessels. Thus, we evaluated the possible relationship existing between VEGF and MIF expression in corneal cells during the process of wound healing after the induction of chemical burns via immunohistochemistry. Furthermore, we evaluated the effects of exogenous MIF on induced corneal neovascularization using a suture-induced model.



Ninety-three male, 7-week-old C57BL/6 mice (Dooyeol Biotech, Seoul, Korea) were used in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research. The experimental protocol was approved by the Institutional Animal Care and Use Committee of Dongguk University.

Ten mice were used as a control group. The eyes and lacrimal glands were harvested after euthanizing the animals (overdose sedation using xylazine and ketamine before cervical dislocation). Ten samples from the right eyes were used for RNA extraction and real-time RT–PCR, and 10 samples from the left eyes were fixed in formalin and used for histology and immunohistochemistry. Another 75 mice were divided into groups 1, 2, and 3 (n=25, each group). After induction of chemical burns in the right eyes (0.1 M NaOH, 20 µl application on the ocular surface for 30 s with no washing), group 1 mice were sacrificed 48 h after chemical burn induction, group 2 mice were sacrificed 7 days after chemical burn induction, and group 3 mice were sacrificed 30 days after chemical burn induction. The eyes and lacrimal glands were harvested from both the right and left sides. The tissues from the left side were used as controls. Fifteen right eyes of each group were used for RNA extraction and real-time RT–PCR, five right eyes of each group were used for histology and immunohistochemistry, and five right eyes of each group were used for protein extraction and western blot analysis. Another eight mice received 8–0 polyglactin (Catalog no:W9560; Coated Vicryl; Ethicon, Cornelia, GA) corneal sutures to induce the formation of new corneal vessels.

Quantitative real-time reverse transcription PCR

Enucleation was performed, and the main lacrimal gland was harvested en bloc. The ocular surface tissues containing the whole cornea, conjunctiva, and the anterior half of the sclera were obtained. Total RNA was isolated from the ocular surface and lacrimal gland using an RNeasy kit (Qiagen, Valencia, CA) in accordance with the manufacturer’s instructions. The RNA concentrations were determined via ultraviolet spectrophotometry. RNA samples were treated with DNase I (Catalog No. 18047–019; Invitrogen, Carlsbad, CA) to preclude genomic DNA contamination. The first-strand cDNA was synthesized from 1 µg of total RNA with oligo d'-T primer using a commercially available kit (SuperScriptTM Ш Reverse Transcriptase; Invitrogen, Carlsbad, CA). Aliquots of samples of cDNA were stored at –80 °C until use. Real-time quantitative PCR was conducted and analyzed with a Roche Light-Cycler. (LightCycler 1536; Roche, Basel, Switzerland) Reactions in a 20 µl volume were conducted using SYBR Green reaction mix (Qiagen) with 0.5 mM of primer. Cyclophilin A was used as normalization standard. Assays were conducted in triplicate. The measured value of the right organ was compared to the measured value of the left organ in each mouse. The value of the right organ divided by the value of the left organ was employed for analysis. The sequences of the PCR primer pairs are listed in Table 1.

Histology and immunohistochemistry

Harvested tissues were formalin fixed and paraffin blocks were prepared. Four micron-thick sections were obtained from formalin-fixed, paraffin-embedded tissues, transferred onto adhesive slides, and dried at 60 °C for 40 min. The immunohistochemical procedures were then conducted using a BenchMark XT automatic immunohistochemical staining device (Ventana Medical System, Tucson, AZ). After dewaxing and rehydrating, antigen retrieval was performed. The slides were then incubated for 30 min at 42 °C with MIF polyclonal antibodies (1:2,000, Catalog no: 36–7401; Zymed, Carlsbad, CA) or VEGF monoclonal antibodies (1:200, Catalog no: ab1316; Abcam, Cambridge, MA). The primary antibodies were detected using an iVIEW DAB detection kit (Ventana Medical System).

Western blot analysis

For western blot analysis, the ocular surface tissues stored at –80 °C were quickly homogenized with a tissue crusher while frozen, and the tissue powder was placed into boiling lysis buffer (1% sodium dodecyl sulface, 1.0 mM sodium ortho-vanadate, 10 mM Tris [pH 7.4]), placed into a microwave oven for 15 s, and centrifuged for 5 min at 11,400× g at 15 °C. The samples were then separated via SDS–PAGE under denaturing conditions and electroblotted onto a polyvinylidine difluoride membrane (BioRad, Hercules, CA). After being blocked using 5% nonfat dry milk in Tris-buffered saline containing 10 mM Tris (pH 7.6), 150 mM NaCl, and 0.1% Tween-20, the membranes were incubated with rabbit antimouse MIF polyclonal antibodies (Catalog no: 36–7401; Zymed) and diluted to 1:200 in blocking solution overnight at 4 °C. The membranes were further incubated with an antirabbit horseradish peroxidase-conjugated antibody (Santa Cruz Biotechnology, Santa Cruz, CA). They were then treated with an enhanced chemiluminescence solution (ECL kit; Pierce, Rockford, IL), and the signals were captured on an image reader (Las-3000; Fuji Photo Film, Tokyo, Japan). To monitor the amount of protein loaded into each lane, the membranes were treated with a stripping buffer and reprobed with a monoclonal antibody against β-actin (Sigma-Aldrich, St Louis, MO). The protein bands were analyzed via densitometry. The ratio between the control and sample was calculated asfollows:

Mouse corneal neovascularization assay

Mouse corneal neovascularization was induced using a 3-mm bite length of 8–0 polyglactin suture near the limbus. Eight mice were used. The right eyes received sutures incubated in recombinant mouse MIF (10 μg/ml, Catalog No: 1978-MF; R&D Systems, Minneapolis, MN) for 48 h. The left eyes received sutures incubated in PBS (Catalog No: 14190–250, no magnesium, no calcium, no phenol red; GIBCO, Grand island, NY) for 48 h. After 7 days, both the cornea and conjunctiva were digitally photographed (Nikon D3000; Nikon, Tokyo, Japan) and angiogenesis scoring was conducted. Angiogenic activity was scored as the number of newly developed vessels crossing the limbus, which was readily visible on the pictures. Mean angiogenic activity was compared between the right and left eyes.

Statistical analysis

SPSS version 12.0 for Windows (SPSS Inc. Chicago, IL) was used for statistical analysis. Mann–Whitney tests were conducted for analysis of difference between the two groups. The Kruskal–Wallis test and least significant difference test (using ranks for multiple comparisons) were used for analyses of the difference between three or more groups. A p value of less than 0.05 was prospectively assigned as the threshold for statistical significance.


Histology of chemical burn of murine ocular surface

Eyes evidenced severe inflammation after the induction of chemical burns by NaOH. The corneas were grossly swollen and hazy. Heavy infiltration by inflammatory cells was observed at full thickness in the cornea, and was particularly severe in the superficial layer. Occasionally, the total absence of epithelial layers and a marked reduction in endothelial cells were noted. This acute change recovered partially over 4 weeks, although the increased corneal thickness and cellularity persisted (Figure 1).

Macrophage migration inhibitory factor and vascular endothelial growth factor immunohistochemistry

MIF was expressed in the corneal epithelium, corneal endothelium, conjunctival epithelium, lens epithelium, and ciliary body epithelium. In the epithelial layer of the cornea, MIF staining was positive with more prominent expression in the basal cells. The corneal stromal layer was negative for MIF staining (Figure 2).

After chemical burn induction, MIF staining could be readily observed in the corneal stromal layer in all samples. However, the infiltrating inflammatory cells were mostly negative for MIF. Interestingly, MIF was expressed in cells around the microvessels and evidenced a high degree of spatial similarity with VEGF expression (Figure 3). Whereas the corneal changes were prominent, the conjunctival changes were difficult to discriminate, owing to scanty tissue in the mice.

Real-time RT–PCR for macrophage migration inhibitory factor, interleukin-1β and tumor necrosis factor-α

The mRNA expression levels of MIF, IL-1β, and TNF-α were evaluated via real-time RT–PCR. In the ocular surface, MIF, IL-1β, and TNF-α expression were significantly elevated after chemical burn induction on days 2, 7, and 30. MIF and TNF-α expression increased steadily for 4 weeks after injury. However, the elevation of IL-1β was dramatic at day 2 and then decreased over a 4-week period but consistently was maintained at elevated levels relative to the controls (Figure 4). MIF and IL-1β in the lacrimal gland evidenced no significant changes after chemical injury to the ocular surface. However, the expression level of TNF-α was increased significantly on days 2 and 7 after injury. This change in TNF-α normalized on day 30 after injury (Figure 4).

Western blot analysis

Western blot analysis of MIF in the ocular surface revealed significant elevation on days 2, 7, and 30 (Figure 5). However, western blot analysis of MIF in the lacrimal gland revealed no significant elevation after chemical burn induction (Figure 5).

Induction of mouse corneal neovascularization with macrophage migration inhibitory factor

Sutures induced significant corneal neo-vessels, using both PBS-incubated or MIF-incubated polyglactin. However, angiogenic activity (vessel score) was significantly higher in the MIF-incubated polyglactin (p=0.003, Mann–Whitney test) relative to the PBS controls on day 7 after suture placement (Figure 6).


Our data reveal that MIF plays a prominent role in the alkali-burned murine eye. On the ocular surface after chemical burn induction, MIF protein was expressed at elevated levels (real-time RT–PCR and western blot) and was abundantly noted in the corneal stromal cells, which normally lack MIF expression. The infiltrating inflammatory cells were negative for MIF expression. Additionally, MIF expression was prominent in the cells surrounding microvessels and was co-localized with VEGF expression. Real-time PCR showed that the kinetics of MIF expression were similar to other inflammatory cytokines, including TNF-α and IL-1β. MIF mRNA was elevated in the ocular surface for 4 weeks after injury. In the lacrimal glands, MIF protein and mRNA were not elevated at any time. Because VEGF is one of the best known cytokines involved in the induction of new vessels under pathologic conditions, the co-existence of MIF and VEGF in similar locations indicates that MIF plays an important role in corneal neovascularization. Here, we induced new vessels using a suture technique and demonstrated that the exogenous application of MIF together with sutures significantly enhances new vessel formation in the mouse cornea.

MIF performs many interesting biologic functions. MIF has been described previously as important in the immune response [1,2,5], angiogenic [23,24], both a promoter and an inhibitor of wound healing [3,7,8], a promoter of fibrosis [8,25-28], an upregulator of matrix metalloproteinases in the promotion of vessel growth [29-31], and a promoter of angiogenic factors, such as VEGF and IL-8 [32,33].

In our study we determined that MIF is abundantly expressed in corneal stromal cells, and the distribution of MIF in the corneal stroma closely matches that of VEGF. This finding is consistent with previous reports revealing that MIF promotes VEGF and together with the destruction of stroma via the upregulation of metalloproteinases, MIF and VEGF may enhance the formation and growth of new vessels. Additionally, we determined that MIF expression was absent in infiltrating corneal inflammatory cells; this result differs from the previously reported finding that MIF was found principally in infiltrating cells in the corneal stroma after ocular surface injury [19]. The finding that MIF expression in the corneal stroma increased while inflammation subsided during the wound healing process also reflects that increased MIF originated principally from corneal stromal cells.

Interestingly, the cells involved in microvessel construction were positive for both MIF and VEGF. Furthermore, the kinetics of MIF expression were correlated with inflammatory cytokines, such as TNF-α and IL-1. This suggests that MIF interacts not only with VEGF but also with other inflammatory cytokines in our ocular chemical burn model. MIF was previously determined to induce TNF-α and IL-1 β expression from the peripheral blood mononuclear cells [34]. Additionally, TNF-α was reported to induce the secretion of MIF from dendritic cells and ovarian cancer cells [35,36]. Recently, anti-TNF therapy resulted in reduced serum MIF levels in patients with rheumatoid arthritis [37]. Therefore, these cytokines may cross-regulate one another in the pathologic cornea and participate in the wound healing response.

Whether the elevation of MIF on the ocular surface promotes or delays wound healing remains to be clearly elucidated. In a previous report it was determined that MIF was advantageous for corneal recovery after ultraviolet-induced photokeratitis in mice [38]. However, when considering both the pro-inflammatory and angiogenic effects of MIF, further studies will be necessary to clarify the role of MIF in ocular surface wound healing.

It is interesting to note that MIF and IL-1β in the lacrimal gland evidenced no significant changes during the wound healing process after chemical burn induction, whereas TNF-α in the lacrimal gland was significantly elevated in the same period. In our previous reports using the botulinum toxin B-induced murine dry eye model, TNF-α and IL-1β were increased on both the ocular surface and lacrimal gland, whereas MIF was increased only in the lacrimal gland [21,22]. Considering the differences in pathogenesis between chemical burn and dry eye, the discrepancy in cytokine expression in the two different disease models is quite understandable.

In the clinical setting the wound healing response after severe ocular surface chemical burns is usually accompanied by corneal haziness, fibrosis, and neovascularization [11]. A variety of therapeutic strategies, including limbal stem cell transplantation, amniotic membrane application, and autologous serum eye drops, have been used in attempts to re-establish the destroyed ocular surface following severe chemical burns [11-13,39]. However, if the inflammation caused by a chemical burn can be minimized via early intervention with an effective therapeutic agent, the overall prognosis of the disease would be likely to improve. Therefore, investigations into appropriate candidate molecules are very important. The targeting of matrix metalloproteinase and VEGF have already yielded significant results [40-42]. Considering the nature of ocular chemical burns, molecules involved in both inflammation and angiogenesis, such as MIF, should be included as targets for future therapeutic interventions.

In conclusion, the data collected herein demonstrate the significance of MIF in the wound healing process following injuries to the ocular surface. Modulating MIF on the ocular surface after a chemical burn may offer new opportunities to improve visual outcomes.


This work was supported by a Korea Research Foundation Grant (MOEHRD, Basic Research Promotion Fund; KRF-2008-A0173–00008).


  1. David JR. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA. 1966; 56:72-7. [PMID: 5229858]
  2. Nishihira J. Macrophage migration inhibitory factor (MIF): its essential role in the immune system and cell growth. J Interferon Cytokine Res. 2000; 20:751-62. [PMID: 11032394]
  3. Hardman MJ, Waite A, Zeef L, Burow M, Nakayama T, Ashcroft GS. Macrophage migration inhibitory factor: a central regulator of wound healing. Am J Pathol. 2005; 167:1561-74. [PMID: 16314470]
  4. Bach JP, Deuster O, Balzer-Geldsetzer M, Meyer B, Dodel R, Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer. 2009; 115:2031-40. [PMID: 19326434]
  5. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003; 3:791-800. [PMID: 14502271]
  6. Park CY, Shin YJ, Lekhanont K, Zhang C, Lee WS, Cano M, Bucala R, Chuck RS. High expression of macrophage migration inhibitory factor in the murine lacrimal gland. Cornea. 2010; 29:187-91. [PMID: 19966563]
  7. Abe R, Peng T, Sailors J, Bucala R, Metz CN. Enhancement of macrophage migration inhibitory factor (MIF) expression in injured epidermis and cultured fibroblasts. Biochim Biophys Acta. 2000; 1500:1-9. [PMID: 10564712]
  8. Dewor M, Steffens G, Krohn R, Weber C, Baron J, Bernhagen J. Macrophage migration inhibitory factor (MIF) promotes fibroblast migration in scratch-wounded monolayers in vitro. FEBS Lett. 2007; 581:4734-42. [PMID: 17854804]
  9. Bondza PK, Metz CN, Akoum A. Macrophage migration inhibitory factor up-regulates alpha(v)beta(3) integrin and vascular endothelial growth factor expression in endometrial adenocarcinoma cell line Ishikawa. J Reprod Immunol. 2008; 77:142-51. [PMID: 17854909]
  10. Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X, Zhang Y, Wang S. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett. 2008; 261:147-57. [PMID: 18171602]
  11. Lim P, Fuchsluger TA, Jurkunas UV. Limbal stem cell deficiency and corneal neovascularization. Semin Ophthalmol. 2009; 24:139-48. [PMID: 19437349]
  12. Pauklin M, Fuchsluger TA, Westekemper H, Steuhl KP, Meller D. Midterm results of cultivated autologous and allogeneic limbal epithelial transplantation in limbal stem cell deficiency. Dev Ophthalmol. 2010; 45:57-70. [PMID: 20502027]
  13. Fish R, Davidson RS. Management of ocular thermal and chemical injuries, including amniotic membrane therapy. Curr Opin Ophthalmol. 2010; 21:317-21. [PMID: 20467317]
  14. Sotozono C, He J, Matsumoto Y, Kita M, Imanishi J, Kinoshita S. Cytokine expression in the alkali-burned cornea. Curr Eye Res. 1997; 16:670-6. [PMID: 9222084]
  15. Planck SR, Rich LF, Ansel JC, Huang XN, Rosenbaum JT. Trauma and alkali burns induce distinct patterns of cytokine gene expression in the rat cornea. Ocul Immunol Inflamm. 1997; 5:95-100. [PMID: 9234373]
  16. Sotozono C, He J, Tei M, Honma Y, Kinoshita S. Effect of metalloproteinase inhibitor on corneal cytokine expression after alkali injury. Invest Ophthalmol Vis Sci. 1999; 40:2430-4. [PMID: 10476814]
  17. Sakimoto T, Yamada A, Kanno H, Sawa M. Upregulation of tumor necrosis factor receptor 1 and TNF-alpha converting enzyme during corneal wound healing. Jpn J Ophthalmol. 2008; 52:393-8. [PMID: 18991041]
  18. Lu P, Li L, Liu G, Zhang X, Mukaida N. Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist. Invest Ophthalmol Vis Sci. 2009; 50:4761-8. [PMID: 19458323]
  19. Usui T, Yamagami S, Kishimoto S, Seiich Y, Nakayama T, Amano S. Role of macrophage migration inhibitory factor in corneal neovascularization. Invest Ophthalmol Vis Sci. 2007; 48:3545-50. [PMID: 17652722]
  20. Gadjeva M, Nagashima J, Zaidi T, Mitchell RA, Pier GB. Inhibition of macrophage migration inhibitory factor ameliorates ocular Pseudomonas aeruginosa-induced keratitis. PLoS Pathog. 2010; 6:e1000826 [PMID: 20361053]
  21. Zhu L, Shen J, Zhang C, Park CY, Kohanim S, Yew M, Parker JS, Chuck RS. Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model. Mol Vis. 2009; 15:250-8. [PMID: 19190733]
  22. Park CY, Zhuang W, Lekhanont K, Zhang C, Cano M, Lee WS, Gehlbach PL, Chuck RS. Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model. Mol Vis. 2007; 13:2222-32. [PMID: 18087241]
  23. Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y, Todo S. Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann N Y Acad Sci. 2003; 995:171-82. [PMID: 12814949]
  24. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res. 2003; 93:321-9. [PMID: 12881477]
  25. Noels H, Bernhagen J, Weber C. Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med. 2009; 19:76-86. [PMID: 19679264]
  26. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008; 28:1897-908. [PMID: 18566299]
  27. Matsumoto K, Maruyama N, Maruyama T, Ohnishi Y, Nonaka S, Inoshita A, Ito K, Kitajima S, Abe M, Satomura A, Fujita T. Elevated macrophage migration inhibitory factor (MIF) levels in the urine of patients with focal glomerular sclerosis. Clin Exp Immunol. 2005; 139:338-47. [PMID: 15654833]
  28. Kim JY, Kwok SK, Hur KH, Kim HJ, Kim NS, Yoo SA, Kim WU, Cho CS. Up-regulated macrophage migration inhibitory factor protects apoptosis of dermal fibroblasts in patients with systemic sclerosis. Clin Exp Immunol. 2008; 152:328-35. [PMID: 18355352]
  29. Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblasts of rheumatoid arthritis. J Biol Chem. 2000; 275:444-50. [PMID: 10617637]
  30. Yu X, Lin SG, Huang XR, Bacher M, Leng L, Bucala R, Lan HY. Macrophage migration inhibitory factor induces MMP-9 expression in macrophages via the MEK-ERK MAP kinase pathway. J Interferon Cytokine Res. 2007; 27:103-9. [PMID: 17316137]
  31. Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK, , 3rd Santos LL, Morand EF, David JR, Koch AE. hage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther. 2006; 8:R132 [PMID: 16872482]
  32. Ren Y, Chan HM, Li Z, Lin C, Nicholls J, Chen CF, Lee PY, Lui V, Bacher M, Tam PK. Upregulation of macrophage migration inhibitory factor contributes to induced N-Myc expression by the activation of ERK signaling pathway and increased expression of interleukin-8 and VEGF in neuroblastoma. Oncogene. 2004; 23:4146-54. [PMID: 15064733]
  33. Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G, Wong J. Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg. 2005; 242:55-63. [PMID: 15973102]
  34. Toh ML, Aeberli D, Lacey D, Yang Y, Santos LL, Clarkson M, Sharma L, Clyne C, Morand EF. Regulation of IL-1 and TNF receptor expression and function by endogenous macrophage migration inhibitory factor. J Immunol. 2006; 177:4818-25. [PMID: 16982923]
  35. Popa C, van Lieshout AW, Roelofs MF, Geurts-Moespot A, van Riel PL, Calandra T, Sweep FC, Radstake TR. MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. Cytokine. 2006; 36:51-6. [PMID: 17166737]
  36. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, Balkwill F. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007; 67:585-92. [PMID: 17234767]
  37. Wijbrandts CA, van Leuven SI, Boom HD, Gerlag DM, Stroes EG, Kastelein JJ, Tak PP. Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis. Ann Rheum Dis. 2009; 68:1316-21. [PMID: 18723565]
  38. Kitaichi N, Shimizu T, Yoshida K, Honda A, Yoshihisa Y, Kase S, Ohgami K, Norisugi O, Makino T, Nishihira J, Yamagishi S, Ohno S. Macrophage migration inhibitory factor ameliorates UV-induced photokeratitis in mice. Exp Eye Res. 2008; 86:929-35. [PMID: 18436209]
  39. Salman IA. Gündo?du C. Epithelial healing in experimental corneal alkali wounds with nondiluted autologous serum eye drops. Cutan Ocul Toxicol. 2010; 29:116-21. [PMID: 20307150]
  40. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007; 48:2545-52. [PMID: 17525183]
  41. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008; 115:e33-8. [PMID: 18439681]
  42. Iwanami H, Ishizaki M, Fukuda Y, Takahashi H. Expression of matrix metalloproteinases (MMP)-12 by myofibroblasts during alkali-burned corneal wound healing. Curr Eye Res. 2009; 34:207-14. [PMID: 19274528]